# Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Study · id `cardio:ct-nct02738151` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02738151](<https://clinicaltrials.gov/study/NCT02738151>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02738151

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 929 participants.

## Technical summary

Registry record NCT02738151. Randomized; no masking; primary purpose treatment. Start 2016-05-19 (registry gives no type); primary completion 2017-08-15 (actual). Results posted on 2018-09-14.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 929 participants (enrolled count; ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Start date: 2016-05-19 (registry gives no type) (ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Primary completion: 2017-08-15 (actual) (ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Completion: 2017-08-15 (actual) (ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Results first posted: 2018-09-14 (ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Croatia; Czechia; Denmark; France; Greece; Hungary; Israel; Italy; Romania; Serbia; Slovakia; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT02738151, source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02738151-2018-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
- Acronym: BRIGHT
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin glargine, 300U/mL
- Intervention (Drug): Insulin degludec, 100 U/mL
- Intervention (Drug): Non-insulin anti-diabetic treatment
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial (`cardio:pubmed-30104294`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c724851a4d77c407acd76152f9c2ef418e530516e41172ea4a9d142572b265ea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
